Immunotherapy combinations with tyrosine-kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) had significantly improved outcomes of patients with mRCC. Predictive and prognostic factors are crucial to improve patients' counseling and management. The present study aimed to externally validate the prognostic value of a previously developed red cell-based score, including hemoglobin (Hb), mean corpuscular volume (MCV) and red cell distribution width (RDW), in patients with mRCC treated with first-line immunotherapy combinations (TKI plus ICI or ICI plus ICI). We performed a sub-analysis of a multicentre retrospective observational study (ARON-1 project) involving patients with mRCC treated with first-line immunotherapy combinations. Uni- and multivariable Cox regression models were used to assess the correlation between the red cell-based score and progression-free survival (PFS), and overall survival (OS). Logistic regression were used to estimate the correlation between the score and the objective response rate (ORR). The prognostic impact of the red cell-based score on PFS and OS was confirmed in the whole population regardless of the immunotherapy combination used [median PFS (mPFS): 17.4 vs 8.2 months, HR 0.66, 95% CI 0.47-0.94; median OS (mOS): 42.0 vs 17.3 months, HR 0.60, 95% CI 0.39-0.92; p < 0.001 for both]. We validated the prognostic significance of the red cell-based score in patients with mRCC treated with first-line immunotherapy combinations. The score is easy to use in daily clinical practice and it might improve patient counselling.
Clinical & experimental metastasis. 2024 Feb 16 [Epub ahead of print]
Michele Maffezzoli, Matteo Santoni, Giulia Mazzaschi, Sara Rodella, Eleonora Lai, Marco Maruzzo, Umberto Basso, Davide Bimbatti, Roberto Iacovelli, Annunziato Anghelone, Ondřej Fiala, Sara Elena Rebuzzi, Giuseppe Fornarini, Cristian Lolli, Francesco Massari, Matteo Rosellini, Veronica Mollica, Cecilia Nasso, Alessandro Acunzo, Enrico Maria Silini, Federico Quaini, Massimo De Filippo, Matteo Brunelli, Giuseppe L Banna, Pasquale Rescigno, Alessio Signori, Sebastiano Buti
Department of Medicine and Surgery, University of Parma, Parma, Italy. ., Oncology Unit, Macerata Hospital, 62100, Macerata, Italy., Department of Medicine and Surgery, University of Parma, Parma, Italy., Department of Oncology, Oncology Unit, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy., Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic., Medical Oncology Unit, Ospedale San Paolo, Savona, Italy., Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy., Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy., Medical Oncology, Ospedale Santa Corona, 17027, Pietra Ligure, Italy., Department of Medicine and Surgery, Section of Radiology, University of Parma, Parma, Italy., Department of Diagnostic and Public Health, Section of Pathology, University of Verona, Verona, Italy., Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK., Centre for Cancer, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK., Section of biostatistics, Department of Health Sciences (DISSAL), University of Genova, Genoa, Italy.